Replies to post #108329 on Biotech Values

[DewDiligence]

While the results of the EMINENCE trial was successful, I'm not sure whether the degree of success would position M118 with Lovenox or the new drugs coming on line.

Actually, the main competition for M118 is Angiomax.

Lovenox is not a major player in ACS, and the new oral anticoagulants have not yet produced compelling ACS data (e.g. #msg-39151366). Moreover, the new oral anticoagulants are not reversible, which is a significant drawback in acute-care settings.

Please see #msg-39146357 for background info.